Clinical Trial Update: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]

View source ↗

Summary

A Phase II randomized trial evaluating a Bruton tyrosine kinase inhibitor with or without venetoclax in veterans with chronic lymphocytic leukemia or small lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bruton tyrosine kinase inhibitor
• Venclexta (venetoclax) (venetoclax)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING